...
首页> 外文期刊>Vaccine >Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants
【24h】

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants

机译:评估第二代重组炭疽疫苗与含铝佐剂的相容性

获取原文
获取原文并翻译 | 示例
           

摘要

Recombinant protective antigen (rPA) is the active pharmaceutical ingredient in a second generation anthrax vaccine undergoing pre-clinical evaluation. This rPA vaccine differs from the currently licensed vaccine, anthrax vaccine adsorbed (AVA), in that the sole component is a recombinant form of protective antigen (PA). Unlike AVA the rPA vaccine contains no lethal factor (LF) or edema factor (EF), components of the two bipartite toxins, nor many other Bacillus anthracis-related contaminating proteins that are present in AVA. The proposed clinical protocol involves adsorption of the rPA to an aluminum-based adjuvant. The adsorptive characteristics of rPA and two aluminum-containing adjuvants were examined in a physiological buffer with and without EDTA. Based on the pI of rPA (pI = 5.6) and the zero charge point of aluminum hydroxide adjuvant (11.5) and aluminum phosphate adjuvant (4.5), it was predicted and demonstrated that rPA bound in a more efficient manner to aluminum hydroxide adjuvant than to aluminum phosphate adjuvant in the physiological buffer. Binding of the rPA to the aluminum hydroxide adjuvant was decreased by increasing amounts of phosphate in the buffer. The adsorptive capacity for rPA onto aluminum hydroxide adjuvant in the physiological buffer and in water were calculated to be 0.46 mg rPA/mg aluminum in DPBS and 0.73 mg rPA/mg aluminum in water. This study also demonstrated that upon desorption from the aluminum hydroxide adjuvant the rPA was physically intact and free of detectable aggregates. Further, the eluted material was biologically active in an in vitro cytotoxicity assay. Desorption was only possible after an overnight incubation of 2-8 degreesC and not after a room temperature incubation reflecting increased contact with the aluminum hydroxide adjuvant over time. These data suggest that the interaction between rPA and aluminum hydroxide adjuvant is predominantly electrostatic in character.
机译:重组保护性抗原(rPA)是经过临床前评估的第二代炭疽疫苗中的活性药物成分。该rPA疫苗与当前许可的吸附炭疽疫苗(AVA)不同,唯一的成分是重组形式的保护性抗原(PA)。与AVA不同,rPA疫苗不含致死因子(LF)或浮肿因子(EF),两种二联毒素的成分,也不包含AVA中存在的许多其他炭疽杆菌相关污染蛋白。拟议的临床方案包括将rPA吸附到铝基佐剂上。在有和没有EDTA的生理缓冲液中检查了rPA和两种含铝佐剂的吸附特性。根据rPA的pI(pI = 5.6)和氢氧化铝佐剂(11.5)和磷酸铝佐剂(4.5)的零电荷点,可以预测和证明rPA与氢氧化铝佐剂的结合更有效。生理缓冲液中的磷酸铝佐剂。通过增加缓冲液中磷酸盐的量,rPA与氢氧化铝佐剂的结合降低。在生理缓冲液和水中,rPA对氢氧化铝佐剂的吸附能力经计算为在DPBS中为0.46 mg rPA / mg铝和在水中为0.73 mg rPA / mg铝。该研究还表明,从氢氧化铝佐剂解吸后,rPA物理上完整无任何聚集体。此外,洗脱的物质在体外细胞毒性测定中具有生物活性。只有在2-8摄氏度的过夜温育后才可能发生解吸,而在室温温育后则无法解吸,这反映出随着时间的推移与氢氧化铝佐剂的接触增加。这些数据表明,rPA和氢氧化铝佐剂之间的相互作用主要是静电特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号